Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy

Detalhes bibliográficos
Autor(a) principal: Carvalho, Fabricio de [UNIFESP]
Data de Publicação: 2012
Outros Autores: Vettore, Andre L. [UNIFESP], Colleoni, Gisele W. B. [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1155/2012/257695
http://repositorio.unifesp.br/handle/11600/34367
Resumo: Cancer/Testis Antigens (CTAs) are a promising class of tumor antigens that have a limited expression in somatic tissues (testis, ovary, fetal, and placental cells). Aberrant expression of CTAs in cancer cells may lead to abnormal chromosome segregation and aneuploidy. CTAs are regulated by epigenetic mechanisms (DNA methylation and acetylation of histones) and are attractive targets for immunotherapy in cancer because the gonads are immune privileged organs and anti-CTA immune response can be tumor-specific. Multiple myeloma (MM) is an incurable hematological malignancy, and several CTAs have been detected in many MM cell lines and patients. Among CTAs expressed in MM we must highlight the MAGE-C1/CT7 located on the X chromosome and expressed specificity in the malignant plasma cells. MAGE-C1/CT7 seems to be related to disease progression and functional studies suggests that this CTA might play a role in cell cycle and mainly in survival of malignant plasma cells, protecting myeloma cells against spontaneous as well as drug-induced apoptosis.
id UFSP_5035e793b66b7b3daa32b89ae6911bb2
oai_identifier_str oai:repositorio.unifesp.br/:11600/34367
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma TherapyCancer/Testis Antigens (CTAs) are a promising class of tumor antigens that have a limited expression in somatic tissues (testis, ovary, fetal, and placental cells). Aberrant expression of CTAs in cancer cells may lead to abnormal chromosome segregation and aneuploidy. CTAs are regulated by epigenetic mechanisms (DNA methylation and acetylation of histones) and are attractive targets for immunotherapy in cancer because the gonads are immune privileged organs and anti-CTA immune response can be tumor-specific. Multiple myeloma (MM) is an incurable hematological malignancy, and several CTAs have been detected in many MM cell lines and patients. Among CTAs expressed in MM we must highlight the MAGE-C1/CT7 located on the X chromosome and expressed specificity in the malignant plasma cells. MAGE-C1/CT7 seems to be related to disease progression and functional studies suggests that this CTA might play a role in cell cycle and mainly in survival of malignant plasma cells, protecting myeloma cells against spontaneous as well as drug-induced apoptosis.Universidade Federal de São Paulo, Disciplina Hematol & Hemoterapia, UNIFESP EPM, BR-04023900 Vila Clementino, SP, BrazilUNIFESP, Dept Ciencias Biol, BR-09972270 Diadema, SP, BrazilUniversidade Federal de São Paulo, Disciplina Hematol & Hemoterapia, UNIFESP EPM, BR-04023900 Vila Clementino, SP, BrazilUNIFESP, Dept Ciencias Biol, BR-09972270 Diadema, SP, BrazilWeb of ScienceHindawi Publishing CorporationUniversidade Federal de São Paulo (UNIFESP)Carvalho, Fabricio de [UNIFESP]Vettore, Andre L. [UNIFESP]Colleoni, Gisele W. B. [UNIFESP]2016-01-24T14:17:37Z2016-01-24T14:17:37Z2012-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion7application/pdfhttp://dx.doi.org/10.1155/2012/257695Clinical & Developmental Immunology. New York: Hindawi Publishing Corporation, 7 p., 2012.10.1155/2012/257695WOS000302578400001.pdf1740-2522http://repositorio.unifesp.br/handle/11600/34367WOS:000302578400001engClinical & Developmental Immunologyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-31T23:25:58Zoai:repositorio.unifesp.br/:11600/34367Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-31T23:25:58Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
title Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
spellingShingle Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
Carvalho, Fabricio de [UNIFESP]
title_short Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
title_full Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
title_fullStr Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
title_full_unstemmed Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
title_sort Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy
author Carvalho, Fabricio de [UNIFESP]
author_facet Carvalho, Fabricio de [UNIFESP]
Vettore, Andre L. [UNIFESP]
Colleoni, Gisele W. B. [UNIFESP]
author_role author
author2 Vettore, Andre L. [UNIFESP]
Colleoni, Gisele W. B. [UNIFESP]
author2_role author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Carvalho, Fabricio de [UNIFESP]
Vettore, Andre L. [UNIFESP]
Colleoni, Gisele W. B. [UNIFESP]
description Cancer/Testis Antigens (CTAs) are a promising class of tumor antigens that have a limited expression in somatic tissues (testis, ovary, fetal, and placental cells). Aberrant expression of CTAs in cancer cells may lead to abnormal chromosome segregation and aneuploidy. CTAs are regulated by epigenetic mechanisms (DNA methylation and acetylation of histones) and are attractive targets for immunotherapy in cancer because the gonads are immune privileged organs and anti-CTA immune response can be tumor-specific. Multiple myeloma (MM) is an incurable hematological malignancy, and several CTAs have been detected in many MM cell lines and patients. Among CTAs expressed in MM we must highlight the MAGE-C1/CT7 located on the X chromosome and expressed specificity in the malignant plasma cells. MAGE-C1/CT7 seems to be related to disease progression and functional studies suggests that this CTA might play a role in cell cycle and mainly in survival of malignant plasma cells, protecting myeloma cells against spontaneous as well as drug-induced apoptosis.
publishDate 2012
dc.date.none.fl_str_mv 2012-01-01
2016-01-24T14:17:37Z
2016-01-24T14:17:37Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1155/2012/257695
Clinical & Developmental Immunology. New York: Hindawi Publishing Corporation, 7 p., 2012.
10.1155/2012/257695
WOS000302578400001.pdf
1740-2522
http://repositorio.unifesp.br/handle/11600/34367
WOS:000302578400001
url http://dx.doi.org/10.1155/2012/257695
http://repositorio.unifesp.br/handle/11600/34367
identifier_str_mv Clinical & Developmental Immunology. New York: Hindawi Publishing Corporation, 7 p., 2012.
10.1155/2012/257695
WOS000302578400001.pdf
1740-2522
WOS:000302578400001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Clinical & Developmental Immunology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 7
application/pdf
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268451841114112